An official website of the United States government
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Indication: For the treatment of cystic fibrosis in patients aged 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
CADTH recommends that Trikafta be reimbursed by public drug plans for the treatment of cystic fibrosis (CF) in patients aged 2 to 5 years and older who have at least one F508del mutation in the CFTR gene, if certain conditions are met. The previous recommendation for Trikafta, for patients who initiate treatment at age 6 years or older, continues to apply to those patients.
Patients who start treatment with Trikafta should be evaluated for response after 1 year, and the treating physician must provide evidence after that the patient is benefiting from the treatment. The cost of Trikafta must also be reduced.
For patients aged 2 to 5 years with CF, Trikafta was well tolerated and shown to improve lung function and reduce sweat chloride in an uncontrolled clinical trial. When used in patients aged 6 years and older, Trikafta was associated with meaningful improvements in lung function, nutritional status, and quality of life, and a reduced rate of pulmonary exacerbations. The committee acknowledged that conducting a comparative clinical study for Trikafta in patients aged 2 to 5 years may be ethically challenging, given the expected balance of risks and benefits of Trikafta in CF based on evidence in patients aged 6 years and older. Given the mechanism of action and efficacy data in patients with CF aged 6 years and older, Trikafta would be expected to benefit patients aged 2 to 5 years who have at least one F508del mutation in the CFTR gene.
Based on CADTH’s assessment of the health economic evidence, Trikafta does not represent good value to the health care system at the public list price. A price reduction is therefore required.
Based on public list prices, Trikafta is estimated to cost the public drug plans approximately $136 million over the next 3 years.
CF is a progressive, fatal, genetic disease that primarily affects the lungs and digestive system. Those living with CF lose the ability to breathe due to accumulated lung damage caused by chronic lung infections and inflammation. F508del is the most common mutation in the CFTR gene that results in CF.
There are significant unmet therapeutic needs for those living with CF. There are no treatments currently available that effectively meet the most important goals of CF therapy: to prolong survival, prevent the need for lung transplant, slow the decline in lung function over time, or reverse the course of the disease.
Treatment with Trikafta is expected to cost $306,810 per patient per year.
The CADTH Canadian Drug Expert Committee (CDEC) recommends that elexacaftor-tezacaftor-ivacaftor and ivacaftor (ELX-TEZ-IVA) be reimbursed for the treatment of cystic fibrosis (CF) in patients aged 2 to 5 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, only if the conditions listed in Table 1 are met.
The CDEC recommendation dated July 2022, for ELX-TEZ-IVA for the treatment of CF in patients who initiate treatment at age 6 years or older who have at least one F508del mutation in the CFTR gene, continues to apply to patients who are not included in the population of this recommendation.
CF is the most common fatal genetic disease affecting children and young adults in Canada. It is caused by mutations in the CFTR gene. Clinical expert input emphasized the importance of initiating treatment early in the disease course and that there is a significant unmet need for a treatment that would prevent disease progression and irreversible CF-related structural lung damage.
For patients aged 2 to 5 years with CF, a 24-week, open-label, uncontrolled trial (Study 111 part B; N = 75) suggested that treatment with ELX-TEZ-IVA resulted in improvements from baseline in lung function (decrease in lung clearance index 2.5% [LCI2.5] from baseline) and CF biomarkers (reduction in sweat chloride) and that the treatment was well tolerated. Study 111 was primarily designed to evaluate safety, tolerability, and pharmacokinetics of ELX-TEZ-IVA, as the regulatory submission was based on the extrapolation of efficacy data from the studies conducted in older patients with CF (i.e., those showing measurable levels of disease manifestations at baseline). Specifically, ELX-TEZ-IVA has demonstrated clinically meaningful improvements in lung function (increase in percent predicted forced expiratory volume in 1 second [ppFEV1]), nutritional status (increase in body mass index [BMI] z score), and health-related quality of life (increase in Cystic Fibrosis Questionnaire – Revised [CFQ-R] respiratory domain scores), and a reduced rate of pulmonary exacerbations, including events that required IV antibiotics and/or hospitalization in clinical trials conducted in patients aged 6 to 11 years (Study 116 [N = 121] and Study 106B [N = 66]) and in patients aged 12 years and older (Study 102 [N = 405], Study 103 [N = 107], Study 109 [N = 107], and Study 104 [N = 259]). CDEC has previously acknowledged that ELX-TEZ-IVA meets some of the important needs identified by patients with CF and their caregivers, such as reducing CF exacerbations, improving health-related quality of life, improving lung function, and improving digestive health allowing people to maintain a healthy body weight; the committee acknowledged that, given the mechanism of action and efficacy data in patients with CF aged 6 years and older, ELX-TEZ-IVA would be expected to benefit patients aged 2 to 5 years who have at least one F508del mutation in the CFTR gene.
Using the sponsor-submitted price for ELX-TEZ-IVA and publicly listed prices for all other drug costs, the incremental cost-effectiveness ratio (ICER) for ELX-TEZ-IVA was $1,284,953 per quality-adjusted life-year (QALY) gained in the F/F genotype, $1,451,526 per QALY gained in the F/MF genotype, $1,284,853 per QALY gained in the F/Gating genotype, and $1,644,869 per QALY gained in the F/RF genotype, compared to best supportive care. Additionally, ELX-TEZ-IVA was associated with an ICER of $838,687 per QALY gained when compared to LUM-IVA in the F/F genotype population. At these ICERs, ELX-TEZ-IVA is not cost-effective at a $50,000 per QALY gained willingness-to-pay threshold for the treatment of CF in patients aged 2 to 5 years who have at least one F508del mutation in the CFTR gene. A price reduction is required for ELX-TEZ-IVA to be considered cost-effective at a $50,000 per QALY gained threshold.
Reimbursement Conditions and Reasons.
Trikafta is a fixed-dose combination product containing elexacaftor, tezacaftor, and ivacaftor co-packaged with ivacaftor (ELX-TEZ-IVA). ELX-TEZ-IVA is available as both oral tablets and oral granules in the following dosage strengths.
Tablets for patients aged 6 years and older:
Granules for patients aged 2 years to younger than 6 years:
ELX-TEZ-IVA is indicated for the treatment of CF in patients aged 2 years and older who have at least one F508del mutation in the CFTR gene. F508del is the most common mutation in the CFTR gene that results in CF. The Canadian Cystic Fibrosis Registry reported that there were 4,344 people in Canada living with CF in 2019. Of these, 87.8% carried at least one F508del mutation (47.1% were homozygous and 40.7% were heterozygous).
This is the third submission to CADTH for ELX-TEZ-IVA. CADTH has previously reviewed ELX-TEZ-IVA for the treatment of CF in patients who have at least one F508del mutation in the CFTR gene for those aged 12 years and older (final recommendation issued in August 2021) and those aged 6 years and older (final recommendation issued in June 2022). For both of the previous reviews, CDEC recommended that ELX-TEZ-IVA be reimbursed with conditions. All of the indications for ELX-TEZ-IVA were accepted as priority reviews by Health Canada.
To make its recommendation, the committee considered the following information:
The information in this section is a summary of input provided by the patient and clinician groups who responded to CADTH’s call for input and from clinical experts consulted by CADTH for the purpose of this review. The complete input received for the previous CADTH reviews of ELX-TEZ-IVA is available on the CADTH website (refer to reviews for ELX-TEZ-IVA for patients aged 6 to 11 years and aged 12 years and older).
One patient group, CF Canada, responded to CADTH’s call for patient input for the current review of ELX-TEZ-IVA, which is focused on patients aged 2 to 5 years who have at least one F508del mutation in the CFTR gene.
The patient groups emphasized that CF tremendously impacts those living with the condition, their loved ones, the health systems, and society. The most significant clinical impact is in the lungs, where patients experience progressive scarring of their airways and a progressive decline in lung function. Young children who grow older with CF may suffer from pulmonary exacerbations requiring weeks to months of hospitalization and IV antibiotics. Malnutrition and low BMI are also common consequences of CF among children aged 2 to 5 years. Patients may also suffer from CF-related comorbidities, such as CF-related diabetes and CF-related liver disease. In addition, CF has a significant impact on socialization, mental health, and isolation among patients and caregivers.
The patient input stated that managing CF requires a demanding treatment routine. As the disease progresses, more time and effort, frequent clinic visits, and hospital stays are needed to manage the progressive and debilitating symptoms. This condition has a significant impact on patients’ and caregivers’ day-to-day activities and quality of life, in addition to a huge financial burden for families.
According to the patient group input, an ideal CF treatment would fully address the basic molecular defect in CF and restore normal chloride transport on the cell surface. Patients with CF and their loved ones are seeking treatments that can change the trajectory of the disease, reduce disease symptoms, improve sleep quality and energy levels, and improve both life expectancy and quality of life.
In the patient group input, CF CanACT emphasized the importance of early treatment of CF to prevent disease progression and irreversible damage. Extending access to ELX-TEZ-IVA to patients with CF aged 2 to 5 years would be congruent with the secondary prevention paradigm of CF care, and would decrease the long-term burden of the disease.
Similar to the input from the patient groups, the clinical experts consulted by CADTH indicated that there are significant unmet therapeutic needs for patients living with CF. There are no treatments currently available that can meet the most important goals of therapy, including: prolonging survival, preventing the need for lung transplant, slowing the decline in lung function over time, or reverse the course of the disease. In addition, the clinical experts noted that the current standard treatments for CF are burdensome for patients and their caregivers.
The clinical experts anticipate that ELX-TEZ-IVA would be used as a preventive therapy with the goal of initiating treatment before the patient develops significant lung disease. The current treatment paradigm would be significantly altered if ELX-TEZ-IVA can successfully prevent or delay progression to end organ disease (e.g., lung transplant). The clinical experts consulted by CADTH and those who responded to the call for clinician input noted that children aged between 2 years and 5 years will often have structural lung disease (e.g., bronchial wall thickening, mucus plugging, bronchiectasis), but that detection is challenging using the tools that are available to evaluate lung function in clinical practice (i.e., spirometry) or as part of a research protocol (e.g., lung clearance index). These early stages of lung abnormalities can be visualized using CT; therefore, despite younger patients with CF often demonstrating normal lung function, the underlying disease will continue to progress.
All of the clinicians who provided input for this review recommended initiating treatment with ELX-TEZ-IVA as soon as possible. This is aligned with the previously published Canadian Clinical Consensus Guideline for Initiation, Monitoring and Discontinuation of CFTR Modulator Therapies for Patients with Cystic Fibrosis, which also recommend that CFTR modulators be initiated at the youngest age possible with the goal of attenuating disease progression and improving clinical status. All stakeholders were in agreement that there are no data to support withholding the initiation of CFTR modulator treatment until clinical symptoms of CF have developed.
For the expanded indication (i.e., those aged 2 to 5 years), the clinical experts consulted by CADTH noted that nearly all patients would initiate therapy with ELX-TEZ-IVA as soon as possible provided it is safe to start to treatment. The clinical experts emphasized that ELX-TEZ-IVA has been a transformative and disease-modifying therapy for CF, and that it would not be appropriate to wait until the patient shows worsening symptoms, more frequent exacerbations, or a decline in lung function to initiate treatment with ELX-TEZ-IVA.
In discussions with CADTH, the sponsor noted that nearly all patients in Canada aged 12 years and older who are eligible for treatment have initiated therapy with ELX-TEZ-IVA (some may have elected to discontinue, but all who are interested have been given the opportunity to access the drug). The sponsor similarly stated that nearly all patients in Canada aged 6 to 11 years who wish to initiate treatment will have initiated treatment with ELX-TEZ-IVA by the end of this calendar year. For those who have initiated treatment with ELX-TEZ-IVA, the sponsor noted that initial renewal criteria were met for all patients in Canada who started the therapy and wanted to continue (i.e., 100% of patients met the renewal criteria recommended by CADTH and/or applied by the public drug programs). The clinical experts consulted expressed general agreement with the sponsor’s position, noting that rates of initial access and renewal are very high within their individual clinics. With nearly all patients who are at least 6 years of age having met the initiation and renewal criteria, newly issued CADTH reimbursement criteria focusing exclusively on those aged 2 to 5 years would effectively replace the previous criteria (i.e., although limited to those aged 2 to 5 years, all older patients would have already qualified for initiation and renewal).
The clinical experts consulted by CADTH reviewed the existing criteria that have been recommended for patients aged 6 years and older and noted the following:
Three groups of clinicians responded to CADTH’s call for input: CF CanACT, the CF Canada Health Care Advisory Council, and the Canadian Cystic Fibrosis Clinician groups. The input from the clinician groups identified the same unmet medical needs for patients with CF and potential place in therapy for the drug under review as the clinical experts consulted by CADTH.
According to the clinician group input, the treatment paradigm for CF in children aged 2 to 5 years is lifelong. All clinician groups noted that available treatments address the symptoms and complications of CF and attempt to slow down the eventual fatal progression of the disease without effectively addressing the root cause or reversing the course of the disease. They also have significant side effects and numerous drug interactions. Clinician groups emphasized that ELX-TEZ-IVA is the most effective improvement of the existing CFTR modulators as it addresses the underlying disease process which helps in delaying disease progression and the need for other therapies, including lung transplant. Therefore, any patient with CF who has at least 1 copy of F508del could potentially benefit from ELX-TEZ-IVA.
Input was obtained from the drug programs that participate in the CADTH reimbursement review process. The clinical experts consulted by CADTH provided advice on the potential implementation issues raised by the drug programs.
Responses to Questions From the Drug Programs.
The evidence identified in the current review of ELX-TEZ-IVA that addressed the expanded patient population (i.e., those aged 2 to 5 years) included Study 111, a 24-week, open-label, phase III, nonrandomized, single-arm, 2-part (A and B) study. Study 111 was conducted in 2 parts:
Patients were eligible to be included in Study 111 if they had received a diagnosis of CF and were aged 2 to 5 years (inclusive). All patients had an F508del CFTR mutation that was either F/MF (69.3%) or F/F (30.7%). Patients were excluded from the study if they had any comorbidities that could impact treatment outcomes, or if they had received a prior hematological or solid organ transplant. The trial excluded patients with a history of colonization with Burkholderia cenocepacia, Burkholderia dolosa, and/or Mycobacterium abscessus. Patients were also considered to be ineligible if they reported an acute upper or lower respiratory infection, a pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease within 4 weeks before the first dose of the study drug. Patients with a history of solid organ or hematological transplant were excluded, as were patients with abnormal laboratory values (e.g., hemoglobin < 10 g/dL), abnormal liver function, or abnormal renal function.
Safety and tolerability were the primary end points in Study 111. Secondary end points were absolute change from baseline in sweat chloride through 24 weeks and absolute change from baseline in LCI2.5. Changes from baseline in growth parameters (BMI, BMI z score, weight, weight z score, height, and height z score) were evaluated as additional efficacy end points, but no statistical analyses were conducted. Descriptive statistics were provided for pulmonary exacerbations and CF-related hospitalizations in Study 111. LCI2.5 was only evaluated in patients who were at least 3 years of age at the time of screening (n = 50).
Treatment with ELX-TEZ-IVA resulted in a within-group improvement (reduction) in sweat chloride from baseline through 24 weeks (least squares [LS] mean absolute change was –57.9 mmol [95% confidence interval (CI), –61.3 to –54.6]; nominal P < 0.0001). The reduction from baseline was observed at all postbaseline assessments (i.e., weeks 4, 12, and 24). Results for the subgroup analyses based on CFTR genotype were–70.0 mmol/L (95% CI, –75.4 to –64.5) in the F/F group and –52.6 mmol/L (95% CI, –56.9 to –48.4) in the F/MF group.
Among those patients who were assessed, treatment with ELX-TEZ-IVA resulted in an improvement (reduction) in LCI2.5 through 24 weeks (within-group LS mean absolute change from baseline –0.83 [95% CI, –1.01 to –0.66]; nominal P < 0.0001). The reduction from baseline was observed at all postbaseline assessments (i.e., weeks 4, 12, and 24). The results were similar in the F/F and F/MF genotype subgroups (LS mean change: –0.89 [95% CI, –1.15 to −0.63] and –0.82 [95% CI, –1.06 to –0.57], respectively).
Sixteen percent of patients experienced a pulmonary exacerbation event through 24 weeks (each patient experience 1 event), with an annualized event rate of 0.32 per year. One patient experienced a pulmonary exacerbation that required hospitalization. There were no CF-related hospitalizations in Study 111.
The absolute changes from baseline in growth end points at 24 weeks were: 0.10 (95% CI, 0.00 to 0.20) for BMI z score; 0.02 (95% CI, –0.04 to 0.09) for body weight z score; and –0.06 (95% CI, –0.11 to 0.00) for height z score.
The overall percentage of patients who experienced at least 1 adverse event (AE) was 98.7% (nearly all were mild [62.7%] or moderate [36.0%] in severity). These AEs included cough (61.3%), increased alanine transaminase (ALT )(10.7%), rhinorrhea (33.3%), increased aspartate aminotransferase (AST) (5.3%), rash (16.0%), pyrexia (34.7%), vomiting (28.0%), COVID-19 (18.7%), nasal congestion (17.3%), upper respiratory tract infection (14.7%), decreased appetite (12.0%), and infective pulmonary exacerbation of CF (10.7%). Two patients (2.7%) experienced serious adverse events (SAEs): 1 patient with anal incontinence, urinary incontinence, and abnormal behaviour [wording from original source]); and 1 patient with an infective pulmonary exacerbation of CF. One patient (1.3%) discontinued treatment due to an SAE and 5 patients (6.7%) had AEs leading to treatment interruption. For AEs of special interest, 8 patients (10.7%) experienced elevated transaminase events and 15 patients (20.0%) experienced rash events (all events were mild or moderate in severity). Two patients experienced rash events leading to treatment interruption. There were no study discontinuations due to rash events or elevated transaminase events.
Study 111 was conducted in a manner similar to all other pivotal studies for the use of CFTR modulators in patients aged 2 to 5 years (i.e., expansion of approval indications for Orkambi and Kalydeco). Each of these studies was conducted in 2 parts, with part A involving a small number of patients (n = 18 for Study 111) with a primary objective of evaluating pharmacokinetics, and part B enrolling more patients (n = 75 for Study 111) with the primary objective of evaluating safety and tolerability. As with the other trials for CFTR modulators in patients aged 2 to 5 years, ELX-TEZ-IVA was administered in an open-label manner in Study 111 and there was no comparator group for either part A or part B. The limited number of secondary efficacy end points evaluated in the study were objective and unlikely to be influenced by the open-label administration of a CFTR modulator (i.e., change from baseline in sweat chloride concentration and change from baseline in LCI2.5).
Pulmonary exacerbations were only evaluated with descriptive statistics and there were no prebaseline or postbaseline comparisons of event rates. In response to an inquiry from CADTH regarding why pulmonary exacerbations were not included as an efficacy end point, the sponsor reported that, similar to the pediatric trial for patients aged 6 to 11 years, exacerbations occur less frequently in younger patients relative to older patients. As Study 111 was a single-arm trial without a defined pretreatment evaluation period, together with the low pulmonary exacerbation rates in the study population, comparison to a pretreatment event rate was not possible.
Eligibility and diagnostic criteria used to screen patients for Study 111 were similar to those used in the other phases of the ELX-TEZ-IVA clinical development program (e.g., Studies 106 and 116 for patients aged 6 to 11 years, and Studies 102, 103, 104, and 109 for patients aged 12 years and older). As noted in the previous CADTH review of ELX-TEZ-IVA, these criteria are generally consistent with Canadian clinical practice for diagnosing patients with CF. As all Canadian provinces and territories have instituted newborn screening, diagnosis of CF and confirmation of genotyping would typically occur early in the child’s life (e.g., an average of 1 month after birth). As such, there would be no changes in diagnostic testing requirements to establish patient eligibility based on CF diagnosis and genotype for the revised age range for ELX-TEZ-IVA.
The clinical experts consulted by CADTH noted that the baseline growth parameters for the patients in Study 111 offered a reasonable reflection of the typical patient in Canadian practice.
Change from baseline in lung function was evaluated as a secondary efficacy end point in Study 111 using LCI2.5. This is reflective of regulatory guidance, which has noted that spirometry may not be sensitive enough to detect treatment differences in children with cystic fibrosis. In addition, spirometry is not typically performed in patients younger than 6 years in Canada, and FEV1 has not been used as a clinical trial end point in any CFTR modulator studies for those younger than 6 years. LCI is used in CF clinical trials as it may be more sensitive in identifying early underlying structural deficiencies within the lungs of patients with CF that cannot be detected using spirometry. Similar to spirometry assessments, the LCI test can be challenging to perform accurately with young children. In Study 111, the sponsor noted that LCI was only performed with patients who were aged at least 3 years at the time of screening. Although LCI is used as an end point in clinical studies, as noted previously, it is not routinely used in Canadian clinical practice and the clinical relevance of differences in this end point have not been characterized. The clinical experts consulted by CADTH indicated that LCI is not reliably correlated with FEV1. A literature review conducted by CADTH found that variable correlation was observed between FEV1 and LCI in children.
ELX-TEZ-IVA was added to the existing therapeutic regimens used by patients, which is reflective of how ELX-TEZ-IVA would be administered in clinical practice. The clinical experts consulted by CADTH indicated that the background therapies used in Study 111 were similar to what would be anticipated in Canadian clinical practice, with the following exacerbations: all patients in Canadian practice would be supplementing with vitamins, and the use of mucolytics (i.e., dornase alfa and inhaled hypertonic saline) could be slightly lower for patients aged 2 to 5 years in Canada.
The 24-week study treatment periods were sufficient for observing change from baseline in sweat chloride and LCI2.5 in Study 111; however, the clinical experts consulted by CADTH suggested that 24 weeks is unlikely to be enough time to observe meaningful changes in BMI for a younger patient population that is relatively healthy. In addition, the absence of a control group in Study 111 limits the ability to interpret the results of change from baseline in the growth parameters.
Patients who completed Study 111 were eligible to enrol in an open-label extension study. However, the sponsor reported that the interim results of the extension study were not available at the time of filing the application with CADTH.
The sponsor conducted an indirect treatment comparison (ITC) to compare the clinical efficacy of ELX-TEZ-IVA in Study 111 with other CFTR modulators in patients with F/F and F/MF mutations to generate inputs needed for the cost-effectiveness analysis. A meta-analysis approach via mixed-effects model for repeated measures (MMRM) was used with individual patient-level data from relevant trials, with data from all comparators being included in 1 model for each genotype. The sponsor concluded that the ITC was not feasible due to the small number of patients in this age group, which reduced the power to detect differences between ELX-TEZ-IVA, LUM-IVA, and/or placebo. As such, the sponsor did not include the ITC comparison in their submission to CADTH and used estimates from the previous CADTH submission for patients aged 6 to 11 years to use as assumptions within their economic model.
To inform the pharmacoeconomic model, the sponsor submitted estimates of clinical efficacy of ELX-TEZ-IVA compared to placebo derived from ITCs that were previously conducted for patients aged 6 to 11 years and 12 years and older, using individual patient data from relevant phase III randomized controlled clinical trials.
The sponsor conducted a single indirect comparison for patients aged 6 to 11 years with an F/F genotype to derive relative estimates of clinical efficacy for: ELX-TEZ-IVA versus LUM-IVA, ELX-TEZ-IVA versus placebo, and ELX-TEZ-IVA versus TEZ-IVA. TEZ-IVA is not currently approved by Health Canada or reimbursed by the Canadian public drug programs for use in patients aged 6 to 11 years. To conduct the primary indirect comparisons, the sponsor extracted 24-week individual patient data for those with an F/F genotype from the following studies: Study 106B for ELX-TEZ-IVA (N = 29), pooled data from Study 809-109 and Study 809-011B for LUM-IVA (N = 160), and Study 661-113B (N = 61) for TEZ-IVA. Additional sensitivity analyses were performed using 8-week data. The sponsor reported the following indirect estimate of effect for ELX-TEZ-IVA compared with placebo for absolute change from baseline through 24 weeks: | || || || || | for ppFEV1. The primary limitation of the ITC was the difference in study design across the included studies (Studies 106B, 809-011B, and 661-113B were single-arm, open-label trials; and Studies 809-109 and 661-115 were double-blind, placebo-controlled trials) and differences in baseline characteristics.
The sponsor did not include any additional studies to address gaps in the pivotal trial evidence.
Patient group, clinical expert, and drug program input gathered during this CADTH review, as well as relevant literature, were reviewed to identify ethical considerations relevant to the use of ELX-TEZ-IVA for the treatment of CF in patients aged 2 to 5 years who have at least one F508del mutation in the CFTR gene.
Ethical considerations identified in this review included those related to the following.
Cost and Cost-Effectiveness.
CADTH identified the following key limitations with the sponsor’s analysis: the sponsor’s adjustment of drug costs by a compliance rate for patients underestimates drug costs and the resulting budget impact, the sponsor’s estimate of the proportion of patients switching treatments from LUM-IVA to ELX-TEZ-IVA upon ELX-TEZ-IVA reimbursement may be underestimated, and there is uncertainty regarding the proportion of patients with public drug coverage. The CADTH reanalysis assumed 100% compliance for all drugs. In the CADTH base case, the reimbursement of ELX-TEZ-IVA for the treatment of CF in patients aged 2 to 5 years with at least one F508del CFTR mutation is expected to be $42,404,017 in year 1, $46,295,984 in year 2, and $48,029,320 in year 3. Therefore, the 3-year total is $136,729,321. A CADTH scenario analysis found the budget impact to be sensitive to assumptions around the proportion of patients with public drug coverage.
Dr. James Silvius (Chair), Dr. Sally Bean, Mr. Dan Dunsky, Dr. Alun Edwards, Mr. Bob Gagne, Dr. Ran Goldman, Dr. Allan Grill, Mr. Morris Joseph, Dr. Christine Leong, Dr. Kerry Mansell, Dr. Alicia McCallum, Dr. Srinivas Murthy, Ms. Heather Neville, Dr. Danyaal Raza, Dr. Emily Reynen, and Dr. Peter Zed.
Meeting date: September 28, 2023
Regrets: None
Conflicts of interest: None
Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.
While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.
CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.
This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners’ own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.
Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada’s federal, provincial, or territorial governments or any third-party supplier of information.
This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user’s own risk.
This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.
The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for noncommercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.
Redactions: Confidential information in this document may be redacted at the request of the sponsor in accordance with the CADTH Drug Reimbursement Review Confidentiality Guidelines.
About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.
Funding: CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
Indication: For the treatment of cystic fibrosis in patients aged 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.
Sponsor: Vertex Pharmaceuticals (Canada) Incorporated
Final recommendation: Reimburse with conditions
Copyright © 2023 - Canadian Agency for Drugs and Technologies in Health. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND).
Your browsing activity is empty.
Activity recording is turned off.
See more...
